Consultant-Needed-Insert
X

Find Novel Dermatology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Difluorocyclohexyloxyphenol

            Therapeutic Area: Dermatology Product Name: TFC-1067

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2020

            Details:

            Sirona has made its first shipment of compound, TFC-1067 to Rodan + Fields. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OnabotulinumtoxinA

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mylan Inc.

            Deal Size: $100.0 million Upfront Cash: $25.0 million

            Deal Type: Licensing Agreement June 01, 2020

            Details:

            Mylan has decided to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX® and BOTOX® Cosmetic (onabotulinumtoxinA), the market-leading neuromodulator.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoid based products

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2020

            Details:

            The cannabis research license by Health Canada allows the Crescita to possess cannabis for the purpose of research and development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TFC-1067

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            TFC-1067 demonstrated very good skin compatibility and does not show a sensitizing effect.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Almirall and WuXi Biologics sign strategic collaboration agreement for multiple bispecific antibodies targeting dermatology diseases

            Contact the Supplier

            Lead Product(s): Bispecific antibody

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ALMIRALL

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 09, 2020

            Details:

            With this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis.

            23andMe

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL...

            Contact the Supplier

            Lead Product(s): Bispecific antibody

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ALMIRALL

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 09, 2020

            Details:

            Almirall will secure the rights to develop and commercialize the antibody for worldwide use. This agreement will strengthen Almirall's early-stage research portfolio.